BMP7 Antibody [J15D7] | Primary Antibodies

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 - 1:10000 IP1:150

Application
WB, IP

Reactivity
Mouse, Rat, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
49 kDa 49 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
BMP7 Antibody [J15D7] detects endogenous levels of total BMP7 protein.

Clone
J15D7

Synonym(s)
OP1, BMP7, Bone morphogenetic protein 7, BMP-7, Osteogenic protein 1, OP-1

Background
BMP7, also known as osteogenic protein-1, belongs to the TGF-β superfamily of secreted growth factors that orchestrate tissue morphogenesis, homeostasis, and repair across skeletal, renal, and neural systems. Synthesized as inactive pro-BMP7, it undergoes furin-mediated cleavage to yield the mature disulfide-linked homodimer with a characteristic TGF-β fold featuring wrist and knuckle epitopes for receptor engagement. BMP7 binds preformed heterotetrameric complexes of type I (ALK2/3/6) and type II (BMPRII/ActRIIA/B) serine/threonine kinase receptors; type II phosphorylates type I GS domain, activating its kinase to propagate canonical Smad1/5/8 phosphorylation, complex formation with Smad4, and nuclear translocation to drive target genes like ID1, Runx2, and Msx2 for osteoblast/chondrocyte differentiation. Non-canonical arms engage TAK1-TAB1/2/3 for p38/ERK/JNK MAPKs promoting proliferation/migration, or PI3K-Akt-mTOR inhibiting apoptosis and inflammation. Antagonists like noggin, chordin, gremlin, and follistatin sequester BMP7 extracellularly, while intracellularly Smurf1/2 ubiquitinates receptors/Smads for degradation, and Smad6/7 competitively inhibit R-Smad phosphorylation. Physiologically, BMP7 patterns kidney metanephric mesenchyme via ureteric bud branching and nephron progenitor proliferation, maintains renal epithelial integrity against fibrosis, supports brown adipogenesis, and regulates monocyte polarization toward anti-inflammatory M2 macrophages. TGF-β/Smad3 upregulates Smurf2 to suppress BMP7/Smad1/5/8 while BMP7 reciprocally attenuates TGF-β/Smad3 via miR-29/miR-200 induction countering miR-21/192-driven fibrosis. BMP7 loss exacerbates epithelial-mesenchymal transition, leading to tubulointerstitial scarring; recombinant BMP7 restores Smad balance, reverses EMT, and protects against diabetic nephropathy progression.

Background

BMP7, also known as osteogenic protein-1, belongs to the TGF-β superfamily of secreted growth factors that orchestrate tissue morphogenesis, homeostasis, and repair across skeletal, renal, and neural systems. Synthesized as inactive pro-BMP7, it undergoes furin-mediated cleavage to yield the mature disulfide-linked homodimer with a characteristic TGF-β fold featuring wrist and knuckle epitopes for receptor engagement. BMP7 binds preformed heterotetrameric complexes of type I (ALK2/3/6) and type II (BMPRII/ActRIIA/B) serine/threonine kinase receptors; type II phosphorylates type I GS domain, activating its kinase to propagate canonical Smad1/5/8 phosphorylation, complex formation with Smad4, and nuclear translocation to drive target genes like ID1, Runx2, and Msx2 for osteoblast/chondrocyte differentiation. Non-canonical arms engage TAK1-TAB1/2/3 for p38/ERK/JNK MAPKs promoting proliferation/migration, or PI3K-Akt-mTOR inhibiting apoptosis and inflammation. Antagonists like noggin, chordin, gremlin, and follistatin sequester BMP7 extracellularly, while intracellularly Smurf1/2 ubiquitinates receptors/Smads for degradation, and Smad6/7 competitively inhibit R-Smad phosphorylation. Physiologically, BMP7 patterns kidney metanephric mesenchyme via ureteric bud branching and nephron progenitor proliferation, maintains renal epithelial integrity against fibrosis, supports brown adipogenesis, and regulates monocyte polarization toward anti-inflammatory M2 macrophages. TGF-β/Smad3 upregulates Smurf2 to suppress BMP7/Smad1/5/8 while BMP7 reciprocally attenuates TGF-β/Smad3 via miR-29/miR-200 induction countering miR-21/192-driven fibrosis. BMP7 loss exacerbates epithelial-mesenchymal transition, leading to tubulointerstitial scarring; recombinant BMP7 restores Smad balance, reverses EMT, and protects against diabetic nephropathy progression.

References
https://pubmed.ncbi.nlm.nih.gov/31979268/ https://pubmed.ncbi.nlm.nih.gov/23126427/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%